92
Participants
Start Date
September 14, 2009
Primary Completion Date
January 20, 2011
Study Completion Date
January 20, 2011
SPD489 (lisdexamfetamine dimesylate)
oral, 20, 30, 40, 50, 60, or 70 mg once daily
Placebo matching SPD489 (lisdexamfetamine dimesylate)
oral, once daily
Advanced Bio-Behavioral Sciences, Elmsford
Comprehensive Neuroscience, Inc., Hollis
CRI Worldwide, Philadelphia
Comprehensive NeuroScience, Atlanta
Medical Research Group of Central Florida, Orange City
Segal Institute for Clinical Research (Miami), North Miami
Behavioral Clinical Research, INC, Lauderhill
Stedman Clinical Trials, Tampa
Accurate Clinical Trials, Kissimmee
University of Cincinnati, Cincinnati
Uptown Research Institute, Chicago
J. Gary Booker, MD, APMC, Shreveport
K&S Professional Research Services, Little Rock
University Hills Clinical Research, Irving
Community Clinical Research, Inc., Austin
Apostle Clinical Trials, Inc., Long Beach
Excell Research, Inc., Oceanside
CNRI San Diego & Los Angeles, San Diego
Affiliated Research Institute, San Diego
Artemis Institute for Clinical Research, San Diego
Southcoast Clinical Trials, San Bernardino
Clinical Innovations, Costa Mesa
Neuropsychiatric Research Center of Orange County, Santa Ana
South Coast Clinical Trials, Anaheim
Omega Clinical Trials, Anaheim
Collaborative Neuroscience Network, Inc., Garden Grove
CRI Worldwide, LLC., Willingboro
Lead Sponsor
Shire
INDUSTRY